The interaction between programmed cell death ligand 1 (PD-L1), which is expressed on the
surface of tumor cells, and programmed cell death 1 (PD-1), which is expressed on T cells …

Antibodies targeting programmed cell death protein 1 (PD-1) or its ligand programmed
death-ligand 1 (PD-L1) are profoundly changing the methods to treat cancers with long-term …

Immunotherapy has revolutionized cancer treatment, with the anti-PD-1/PD-L1 axis therapy
demonstrating significant clinical efficacy across various tumor types. However, it should be …

Harnessing the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-
L1) axis is pivotal in autoimmunity and cancer immunotherapy. PD-1 receptors on immune …

Programmed death-ligand 1 (PD-L1) is an immune checkpoint inhibitor that binds to its
receptor PD-1 expressed by T cells and other immune cells to regulate immune responses; …

With programmed death 1/ligand 1 (PD-1/PD-L1) as the cornerstone, anti-PD antibodies
have pioneered revolutionary immunotherapies for malignancies. But most patients …

The advent of immune checkpoint inhibitors has revolutionized cancer therapy by leveraging
the body's immune system to combat malignancies effectively. Among these groundbreaking …

ABSTRACT Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell
checkpoint and plays a central role in regulating T cell exhaustion. Binding of PD-1 to its …

Major progress has been made toward our understanding of the programmed death-
1/programmed death ligand-1 (PD-1/PD-L1) pathway (referred to as the PD pathway). mAbs …

The immunosuppressive molecule programmed death-ligand 1 (PD-L1) is frequently
upregulated in human cancers. Binding of PD-L1 to its receptor, programmed death-1 (PD …